spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Porton Biopharma opens new facility to make more of its childhood cancer cure


In a ribbon cutting ceremony, John Glen MP for Salisbury and South Wiltshire today (27th April 2018) officially opened Porton Biopharma Limited’s (PBL) new fermentation facility which will be used to manufacture the company’s life-saving leukaemia drug Erwinase®.



The state-of-the-art facility has been designed and built around a new 3000 litre fermenter which is a significant increase over existing capacity and will enable PBL to increase the amount of product it will be able to manufacture in the future.

The new multi-million pound building has a footprint of approximately 2100m2. This includes the main fermentation hall, down-stream processing rooms for harvesting product, plus all the associated services of purified water, steam, air and effluent treatment that are required in a modern pharmaceutical facility that meets the latest regulatory standards. These systems have been designed to interact seamlessly and are operated by the latest process-control system. This will enable PBL’s production technicians to easily view and control any of the component parts via a series of hi-tech interactive screens.



Mike Raine Director of Engineering for PBL said “Today represents an important milestone where we can see the physical results of all the hard work in the design, planning and build that have gone into this project. We are now looking forward to the next challenge of qualifying and validating the equipment to ensure that everything is working as specified, before going into full production sometime over the next year.”

Commenting on the ceremony John Glen said, “I was delighted to be welcomed back to open this new facility after having performed the ground-breaking ceremony in May 2016, the transformation of the site is astounding. Having this facility in Wiltshire is also a superb local example of the government’s industrial strategy, which specifically includes supporting the life-sciences sector and building prosperous communities – a good news event for Salisbury!”.

Dr Roger Hinton MD of PBL said “We are looking forward to the day when this facility comes on-line because that, along with the other investments that we have made, means that we will be able to meet the growing global demand for our product. This helps to grow the value of Porton Biopharma Limited, but most importantly it means that we will be able to save the lives of more children who suffer from this form of leukaemia in future.”
 
Print this page
Send to a friend
   
spacer
News and Press Releases

BioIVT to Focus on the Application of In Vitro Hepatocyte Models in Toxicology Research at the North American ISSX Meeting

BioIVT, a leading provider of research models and services for drug development, today announced that it will be participating in several sessions at the 22nd North American International Society for the Study of Xenobiotics (ISSX) Meeting. This conference will be held from July 15-19 at the Palais des congrès de Montréal in Montréal, Canada.
More info >>


White Papers

Sterile Vials Made of Tubular Glass

Gerresheimer AG

Gx® RTF vials powered by Ompi EZ-fill® enhance flexibility by facilitating packaging needs from clinical stage to industrialization with the common goal to minimize customer product risks and optimize total cost of ownership. Gerresheimer combines the competencies in converting glass tubes to serum/ injection vials and ready-to-fill processing for our pharma and biotech customers.
More info >>

Industry Events

6th Annual Single Cell Analysis Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 6th Annual Single Cell Analysis Congress taking place on 8-9 November 2018 in London.  Part of the Genomics & Synthetic Biology Series UK, the congress will bring together over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical and biotech companies.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement